Back to top
more

Quest Diagnostics (DGX)

(Real Time Quote from BATS)

$174.22 USD

174.22
219,626

+0.95 (0.55%)

Updated Aug 6, 2025 11:26 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (67 out of 246)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Can Five Elements Drive Quest Diagnostics (DGX) Q1 Earnings?

by Zacks Equity Research

Quest Diagnostics (DGX) seems in sync with its strategy to expedite growth and operational excellence.

Zacks Equity Research

Quest Diagnostics (DGX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Quest Diagnostics (DGX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Quest Diagnostics Grows on New Pacts Amid Reimbursement Issue

by Zacks Equity Research

Quest Diagnostics' (DGX) partnership with UnitedHealthcare to operate as a preferred national laboratory seems strategic for the latter's customers.

Zacks Equity Research

Quest Diagnostics (DGX) Up 3.5% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Quest Diagnostics (DGX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Should Value Investors Pick Quest Diagnostics (DGX) Stock?

by Zacks Equity Research

Let's see if Quest Diagnostics (DGX) stock is a good choice for value-oriented investors right now from multiple angles.

Zacks Equity Research

Quest Diagnostics Ties Up With RMC to Deliver Lab Services

by Zacks Equity Research

Quest Diagnostic's (DGX) partnership with RMC is set to better the quality of patient care.

Zacks Equity Research

Quest Diagnostics Grows on Innovation Amid Reimbursement Woe

by Zacks Equity Research

Quest Diagnostics' (DGX) progress in prescription drug monitoring, QuantiFERON and non-invasive prenatal screening are part of its recent major developments.

Zacks Equity Research

Quest Diagnostics (DGX) Q4 Earnings in Line, Margins Down

by Zacks Equity Research

In recent times, Quest Diagnostics (DGX) is facing several reimbursement issues which have hurt revenues.

Zacks Equity Research

Quest Diagnostics (DGX) Q4 Earnings Meet Estimates

by Zacks Equity Research

Quest Diagnostics (DGX) delivered earnings and revenue surprises of 0.00% and -2.42%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Can M&A Activity Drive Quest Diagnostics (DGX) Q4 Earnings?

by Zacks Equity Research

Quest Diagnostics' (DGX) increasing partnerships with other health care leaders and strategic acquisitions are promising abundant opportunities for the company's top and bottom-line improvement.

Zacks Equity Research

Earnings Preview: Quest Diagnostics (DGX) Q4 Earnings Expected to Decline

by Zacks Equity Research

Quest Diagnostics (DGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Quest Diagnostics' Core Diagnostics Strong Amid Several Woes

by Zacks Equity Research

Quest Diagnostics' (DGX) steady efforts to intensify focus on core diagnostic information services business and an intelligent capital management give investors ample reasons to cheer for.

Zacks Equity Research

Quest Diagnostics (DGX) Divests India Business to Strand

by Zacks Equity Research

Quest Diagnostics (DGX) sees lucrative prospects in the U.S. diagnostic testing market.

Zacks Equity Research

Amazon Eyeing Diagnostic Space to Gather Steam in Healthcare

by Zacks Equity Research

Amazon's (AMZN) growing healthcare initiatives are likely to aid its growth in the healthcare supply chain management market.

Zacks Equity Research

Myriad Genetics Announces Encouraging EndoPredict Test Data

by Zacks Equity Research

Myriad Genetics (MYGN) forges ahead with initiatives to boost the adoption of the EndoPredict tests.

Zacks Equity Research

Quest Diagnostics Rides on Product Launches, Strategic Deals

by Zacks Equity Research

Quest Diagnostics' (DGX) consistent efforts to refocus on core diagnostic information services business and disciplined capital deployment buoy optimism on the stock.

Zacks Equity Research

Near-Term Outlook for Medical Information Systems Industry

by Zacks Equity Research

The wave of digital transition is helping companies in the Zacks Medical Info Systems industry to create opportunities for investors.

Zacks Equity Research

Company News For Nov 30, 2018

by Zacks Equity Research

Companies In The News Are: DLTR,ANF,DGX,NLSN

Zacks Equity Research

Quest Diagnostics to Buy Laboratory Services Unit in Midwest

by Zacks Equity Research

Quest Diagnostics (DGX) continues to expand inorganically. The latest buyout is expected to expand the company's portfolio in the Midwest.

Zacks Equity Research

Bright Outlook for Outpatient and Home Healthcare Industry

by Zacks Equity Research

Here we discuss how outpatient and home healthcare have been creating opportunities for investors keen on parking their money in this space.

Zacks Equity Research

Quest Diagnostics (DGX) Up 1.9% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Quest Diagnostics (DGX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Quest Diagnostics (DGX) Q3 Earnings Meet, Guidance Tweaked

by Zacks Equity Research

Quest Diagnostics (DGX) gains on successful execution of its strategy of accelerating growth in Q3.

Zacks Equity Research

Quest Diagnostics (DGX) Q3 Earnings Match Estimates

by Zacks Equity Research

Quest Diagnostics (DGX) delivered earnings and revenue surprises of 0.00% and -3.11%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Will 5 Elements Drive Quest Diagnostics (DGX) Q3 Earnings?

by Zacks Equity Research

Quest Diagnostics' (DGX) growing partnerships with health care leaders and strategic acquisitions are expected to boost top and bottom-line growth in Q3.

Zacks Equity Research

Quest Diagnostics (DGX) Q3 Earnings Preview: What's in the Cards?

by Zacks Equity Research

Quest Diagnostics (DGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.